Recent News

• 02.11.2026 - IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
• 02.09.2026 - IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
• 01.28.2026 - IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
• 01.12.2026 - IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
• 12.17.2025 - IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
• 12.10.2025 - IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
• 12.05.2025 - IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Recent Filings

• 02.09.2026 - EX-99.1 EX-99.1
• 02.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.12.2026 - EX-99.1 EX-99.1
• 01.09.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2026 - EX-99.1 EX-99.1
• 01.08.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.17.2025 - EX-99.1 EX-99.1
• 12.10.2025 - EX-99.1 EX-99.1